LeMaitre Vascular (NASDAQ:LMAT) Posts Earnings Results, Misses Expectations By $0.07 EPS

LeMaitre Vascular (NASDAQ:LMAT) announced its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07), FiscalAI reports. The company had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 earnings per share.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q2 organic sales grew 10%, with growth of 12% excluding the temporary catheter recall comparison; operating income rose 26%, EPS increased 23% to $0.74, and operating margin reached a record 29%.
• Artegraft was the fastest-growing product, with sales up 34% and representing 21% of revenue. International sales are expected to reach $11 million in 2026 versus $4 million in 2025, supported by additional country approvals, longer graft sizes, and expanded commercial infrastructure.
• The company reported strong profitability and expansion in Europe, where localized warehouses and sales operations are contributing to significant shipping savings and year-over-year gross-margin gains of roughly 5 to 9 percentage points.
• Full-year revenue guidance was reduced to $276.3 million and organic growth to 11%, reflecting a stronger U.S. dollar, continued Middle East-related export delays, and slower-than-expected cardiac allograft growth because of supply constraints. Operating income guidance was lowered to $76.8 million as the revenue shortfall flows through.
• RestoreFlow and other cardiac allografts remain supply constrained, while the FDA identified additional quality-system observations at the New Jersey facility. The company says production and shipments have not been disrupted, but the QuickStitch project may now require a clinical trial, extending its timeline from quarters to years.

LeMaitre Vascular Price Performance

LMAT traded up $2.17 on Tuesday, reaching $105.78. The company had a trading volume of 405,320 shares, compared to its average volume of 280,216. The company has a market capitalization of $2.42 billion, a P/E ratio of 39.03, a PEG ratio of 2.88 and a beta of 0.53. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average of $97.41 and a 200-day moving average of $100.04. LeMaitre Vascular has a one year low of $79.39 and a one year high of $118.01.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,928 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $107.00, for a total transaction of $313,296.00. Following the sale, the insider directly owned 3,749 shares in the company, valued at approximately $401,143. The trade was a 43.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This represents a 56.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 54,453 shares of company stock worth $5,906,174. 7.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular during the 2nd quarter valued at $47,000. Geneos Wealth Management Inc. lifted its holdings in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares during the period. Quarry LP lifted its holdings in shares of LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after buying an additional 529 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of LeMaitre Vascular in the fourth quarter valued at $68,000. Finally, Kemnay Advisory Services Inc. bought a new position in LeMaitre Vascular during the fourth quarter valued at about $80,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

More LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue rose 9.6% year over year to $70.38 million, while EPS increased from $0.60 to $0.74. The company also reported a healthy 24.35% net margin and announced a quarterly dividend of $0.25 per share. LeMaitre Q2 2026 Financial Results
• Neutral Sentiment: Management projected fourth-quarter 2026 EPS of $0.75–$0.81, broadly around the $0.79 analyst consensus, suggesting some potential for results to meet expectations later in the year.
• Negative Sentiment: Second-quarter EPS of $0.74 missed the $0.81 consensus estimate, and revenue of $70.38 million came in below the $71.47 million forecast. LeMaitre Vascular Earnings Results
• Negative Sentiment: Full-year 2026 guidance was reduced to EPS of $2.84–$2.94 and revenue of $274.3 million–$278.3 million, below consensus estimates of $3.00 EPS and $279.9 million revenue.
• Negative Sentiment: Third-quarter guidance also trailed expectations, with EPS of $0.66–$0.71 versus $0.73 consensus and revenue of $66.3 million–$68.3 million versus $69.0 million expected.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of recent research reports. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Wells Fargo & Company upped their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Citizens Jmp increased their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Finally, Barrington Research reiterated an “outperform” rating and issued a $120.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.